SUMM.L Share News (SUMM)
SUMM Share
SUMM Share
SUMM Share
SUMM Share
SUMM
SUMM Share
SUMM Broker
SUMM Directors
SUMM Financial
SUMM
SUMM Short
SUMMMon, 18th Nov 2013 08:10
Shares in Summit Corporation, an Oxford based drug developer, soared 20 per cent on Tuesday after it announced it has entered a technology licence agreement with Bristol-Myers Squibb Company. Under the agreement, Bristol-Myers will use Summit's Seglin technology to identify and develop drug candida
Read moreLord Wolfson of Aspley Guise, Chief Executive of High Street retailer Next, has made his first sale since March 2007 in a move which triggered a widespread sale of the company's shares. Wolfson, who has stood at the helm of the chain store since 2001, sold off 125,000 shares at 3,057p each for a t
Read moreIt's all go at Oxford based drug developer Summit Corporation as the firm announces a five million pound share placing, appoints a new Chief Executive and reveals encouraging results for an anti-superbug drug. The company says it will issue 166,666,670 new shares at 3p per share to "certain institu
Read moreSummit Corporation, a drug research group, has reported positive data from in vivo studies in its drug discovery programme targeting Alzheimer's disease and related neurodegenerative disorders. The most recent tril has discoved a way to enable the drug to penetrate the Blood Brain Barrier and enter
Read moreDrug discovery company Summit Corporation is in discussions with potential partners for the Seglin platform. The Seglin platform enables the identification of mew treatments. The platform is being used to identify cancer and metabolic diseases treatments. AIM-quoted Summit suffered a operating c
Read moreAIM-quoted Summit Corporation has revealed positive non-clinical efficacy results for SMT C1100, a treatment for Duchenne muscular dystrophy (DMD). The Summit share price rose by nearly one-fifth following the announcement. DMD is caused by the loss of a protein called dystrophin which results in
Read moreDrug discoverer Summit Corporation says that trials of its SMT 19969 C. difficile treatment show that it is superior to existing treatments. Summit has the backing of the Wellcome Trust, which is funding the programme. SMT 19969 provides protection from initial and recurring infections. There is
Read moreXP Power deputy chairman James Peters raised £1.47m from a share disposal two days after bumper interim figures from the power control products supplier. Peters sold 200,000 shares at 735p each. Peters founded XP in 1988 and still owns nearly 2.7m shares, which is equivalent to 14%. That still mak
Read moreSausage casings manufacturer Devro reported a sharp rise in interim profit and a 40% increase in its interim dividend to 2p a share. Pre-exceptional profit was 86% ahead at £17.1m as sales increased 11% to £116.1m in the six months to June 2010. The market for collagen casings is growing at 5% a y
Read more0848 GMT [Dow Jones] Singer Capital Markets initiates coverage of Summit Corp. (SUMM.LN) with an 11p price target. The broker says the drug development and research services firm has a promising therapy for Duchenne muscular dystrophy in early-stage clinical trials with BioMarin (BMRN), as well as a
Read moreBroker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0848 GMT [Dow Jones] Singer Capital Markets initiates coverage of Summit Corp. (SUMM.LN) with an 11p price target. The broker
Read moreLONDON (Dow Jones)--Summit Corporation PLC (SUMM.LN), a U.K. based drug discovery company, said Thursday it has a number of opportunities to deliver commercial success from its portfolio of partner funded programs and Seglin technology platform, adding that it is currently exploring potential collab
Read moreShares in Global Petroleum and Tower Resources slumped after the companies reported that the Avivi-1 well in Uganda had reached its total depth without showing any oil. Avivi-1 is owned by Tower, while Global has an option to earn a 25% interest in the licence, by funding 25% of the costs. 'Electr
Read moreRobert Walker, the chairman-designate of Travis Perkins, has bought his first shares in the builders' merchant. Walker was appointed to the Travis Perkins board on 30 September 2009 and he is due to take over as chairman from Tim Stevenson in May 2010. Walker has bought a total of 25,000 shares at
Read more
